Sachiyo Minegishi

Nessuna posizione attualmente

46 anni

Health Technology

Finance

Consumer Services

Profilo

Sachiyo Minegishi worked as a Senior Director at Aegerion Pharmaceuticals, Inc. from 2012 to 2016, and as a Vice President at bluebird bio, Inc. from 2016 to 2020.
She also worked as the Head of Finance at Akouos, Inc. Ms. Minegishi completed her undergraduate degree at the Massachusetts Institute of Technology and earned an MBA from The Wharton School of the University of Pennsylvania.

Precedenti posizioni note di Sachiyo Minegishi

Società	Posizione	Fine
BLUEBIRD BIO, INC.	Corporate Officer/Principal	01/09/2020
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/04/2016
AKOUOS	Director of Finance/CFO	-

Vedi nel dettaglio l'esperienza di Sachiyo Minegishi

Formazione di Sachiyo Minegishi

Massachusetts Institute of Technology	Undergraduate Degree
The Wharton School of the University of Pennsylvania	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Sachiyo Minegishi

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
BLUEBIRD BIO, INC.	Health Technology

Aziende private	2
Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.	Health Technology
Akouos, Inc. Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.	Health Technology